董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Glenn Muir | 男 | Independent Director | 67 | 20.41万美元 | 33.47 | 2025-07-15 |
| Keith J. Sullivan | -- | Director, President and Chief Executive Officer | -- | 436.51万美元 | 183.80 | 2025-07-15 |
| Robert A. Cascella | -- | Non-Executive Chairman of the Board | -- | 26.82万美元 | 54.20 | 2025-07-15 |
| Sheryl L. Conley | -- | Independent Director | -- | 20.16万美元 | 15.47 | 2025-07-15 |
| Megan R. Rosengarten | -- | Independent Director | -- | 19.76万美元 | 11.09 | 2025-07-15 |
| Sasha S. Cucuz | -- | Independent Director | -- | 18.40万美元 | 199.45 | 2025-07-15 |
| Avinash N. Amin | -- | Independent Director | -- | 11.97万美元 | 1.25 | 2025-07-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Pfanstiel | 男 | Executive Vice President, Chief Financial Officer and Treasurer | 52 | 233.18万美元 | 未持股 | 2025-07-15 |
| Keith J. Sullivan | -- | Director, President and Chief Executive Officer | -- | 436.51万美元 | 183.80 | 2025-07-15 |
| W. Andrew Macan | 男 | Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 53 | 211.45万美元 | 26.93 | 2025-07-15 |
董事简历
中英对照 | 中文 | 英文- Glenn Muir
-
Glenn Muir，他一直担任董事会成员（2017年7月以来）。从1992年到2014年退休，他曾担任Hologic， Inc.（一家上市的医疗产品制造商和供应商）的首席财务官。2000年至2014年，他担任Hologic的财务与行政执行副总裁；1992年至2000年，担任财务与行政副总裁；1988年至1992年，担任财务总监。2001年至2013年，他担任Hologic的董事。1986年至1988年，他担任Metallon Engineered Materials Corp.的首席财务官和财务与行政副总裁。1981年至1984年，他担任Arthur Andersen & Co.的高级审计师。Muir先生自2015年起担任两家公开上市的生命科学和生物技术公司（Repligen Corporation和G1 Therapeutics， Inc.）的董事。2014年至2017年，他担任ReWalk Robotics Ltd.和RainDance Technologies， Inc.的独立董事。他持有Massachusetts大学in Amherst的会计学士学位，Harvard Business School的工商管理硕士学位，以及Bentley College Graduate School of Business的税务硕士学位。他是一名注册会计师。
Glenn Muir has served as a member of board of directors since July 2017. From 1992 until 2014 when he retired, Mr. Muir was the Chief Financial Officer at Hologic, Inc., a publicly-traded manufacturer and supplier of medical products. He served as Hologic's Executive Vice President of Finance & Administration from 2000 to 2014 as Vice President of Finance & Administration from 1992 to 2000 and as Controller from 1988 to 1992. Mr. Muir served as a Director of Hologic from 2001 to 2013. Mr. Muir served as Chief Financial Officer and Vice President of Finance & Administration at Metallon Engineered Materials Corp. from 1986 to 1988. He served as a Senior Auditor with Arthur Andersen & Co. from 1981 to 1984. Mr. Muir has been a Director of two publicly traded life science and biotechnology companies, Repligen Corporation and G1 Therapeutics, Inc., since 2015. He served as an Independent Director at ReWalk Robotics Ltd. and RainDance Technologies, Inc., both from 2014 to 2017. Mr. Muir earned his bachelor's degree in accounting from the University of Massachusetts in Amherst, his M.B.A. from the Harvard Business School, and his M. Sc. in taxation from Bentley College Graduate School of Business. He is a certified public accountant. - Glenn Muir，他一直担任董事会成员（2017年7月以来）。从1992年到2014年退休，他曾担任Hologic， Inc.（一家上市的医疗产品制造商和供应商）的首席财务官。2000年至2014年，他担任Hologic的财务与行政执行副总裁；1992年至2000年，担任财务与行政副总裁；1988年至1992年，担任财务总监。2001年至2013年，他担任Hologic的董事。1986年至1988年，他担任Metallon Engineered Materials Corp.的首席财务官和财务与行政副总裁。1981年至1984年，他担任Arthur Andersen & Co.的高级审计师。Muir先生自2015年起担任两家公开上市的生命科学和生物技术公司（Repligen Corporation和G1 Therapeutics， Inc.）的董事。2014年至2017年，他担任ReWalk Robotics Ltd.和RainDance Technologies， Inc.的独立董事。他持有Massachusetts大学in Amherst的会计学士学位，Harvard Business School的工商管理硕士学位，以及Bentley College Graduate School of Business的税务硕士学位。他是一名注册会计师。
- Glenn Muir has served as a member of board of directors since July 2017. From 1992 until 2014 when he retired, Mr. Muir was the Chief Financial Officer at Hologic, Inc., a publicly-traded manufacturer and supplier of medical products. He served as Hologic's Executive Vice President of Finance & Administration from 2000 to 2014 as Vice President of Finance & Administration from 1992 to 2000 and as Controller from 1988 to 1992. Mr. Muir served as a Director of Hologic from 2001 to 2013. Mr. Muir served as Chief Financial Officer and Vice President of Finance & Administration at Metallon Engineered Materials Corp. from 1986 to 1988. He served as a Senior Auditor with Arthur Andersen & Co. from 1981 to 1984. Mr. Muir has been a Director of two publicly traded life science and biotechnology companies, Repligen Corporation and G1 Therapeutics, Inc., since 2015. He served as an Independent Director at ReWalk Robotics Ltd. and RainDance Technologies, Inc., both from 2014 to 2017. Mr. Muir earned his bachelor's degree in accounting from the University of Massachusetts in Amherst, his M.B.A. from the Harvard Business School, and his M. Sc. in taxation from Bentley College Graduate School of Business. He is a certified public accountant.
- Keith J. Sullivan
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert A. Cascella
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Sheryl L. Conley
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Megan R. Rosengarten
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Sasha S. Cucuz
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Avinash N. Amin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Steven Pfanstiel
Steven Pfanstiel，最近一次任职于Marinus制药，这是一家上市制药公司，专注于罕见疾病和神经科学，2021年4月至2025年3月，最近担任首席财务官和首席运营官。2021年4月至2023年3月，担任Marinus制药首席财务官。从2020年1月至2021年3月，Pfanstiel先生曾担任LifeScan，Inc.（“LifeScan”）的财务副总裁，该公司是一家专注于糖尿病市场的医疗设备公司，负责支持LifeScan的全球商业和开发组织，以及其财务规划和分析金库职能。在加入LifeScan之前，Pfanstiel先生于2018年2月至2020年1月在OptiNose公司（“OptiNose”）担任FP & A高级总监，该公司是一家上市的专业制药公司，专注于耳、鼻、喉和过敏专科医生治疗的疾病。从2016年7月到2018年2月，Pfanstiel先生担任Depuy Synthes Companies的支持全球战略营销高级总监，该公司是强生拥有的骨科和神经外科公司的特许经营权。在其职业生涯的早期，Pfanstiel先生曾在强生担任多个财务职位，包括杨森研发、LifeScan和Ethicon Endo-Surgery。Pfanstiel先生在Wabash学院获得物理学学士学位，在Clemson大学获得环境系统工程硕士学位，在印第安纳大学Kelley商学院获得MBA学位。
Steven Pfanstiel,most recently worked at Marinus Pharmaceuticals, a publicly traded pharmaceutical company specializing in rare diseases and neuroscience, from April 2021 through March 2025, where he most recently served as Chief Financial Officer and Chief Operating Officer. From April 2021 to March 2023, he served as Chief Financial Officer at Marinus Pharmaceuticals. From January 2020 to March 2021, Mr. Pfanstiel previously served as Vice President, Finance of LifeScan, Inc. ("LifeScan"), a medical device company focused on the diabetes market, where he was responsible for supporting LifeScan's global commercial and development organizations, as well as its financial planning and analysis treasury functions. Before LifeScan, Mr. Pfanstiel served as Senior Director of FP&A at OptiNose, Inc. ("OptiNose"), a publicly traded specialty pharmaceutical company focused on diseases treated by ear, nose, and throat and allergy specialists, from February 2018 to January 2020. From July 2016 to February 2018, Mr. Pfanstiel served as Senior Director supporting Global Strategic Marketing for the DePuy Synthes Companies, a franchise of orthopedic and neurosurgery companies owned by Johnson & Johnson. Earlier in his career, Mr. Pfanstiel held various finance positions within Johnson & Johnson, including Janssen R&D, LifeScan, and Ethicon Endo-Surgery. Mr. Pfanstiel received his B.A. in Physics from Wabash College, his M.S. in Environmental Systems Engineering from Clemson University and his MBA from Indiana University, Kelley School of Business.- Steven Pfanstiel，最近一次任职于Marinus制药，这是一家上市制药公司，专注于罕见疾病和神经科学，2021年4月至2025年3月，最近担任首席财务官和首席运营官。2021年4月至2023年3月，担任Marinus制药首席财务官。从2020年1月至2021年3月，Pfanstiel先生曾担任LifeScan，Inc.（“LifeScan”）的财务副总裁，该公司是一家专注于糖尿病市场的医疗设备公司，负责支持LifeScan的全球商业和开发组织，以及其财务规划和分析金库职能。在加入LifeScan之前，Pfanstiel先生于2018年2月至2020年1月在OptiNose公司（“OptiNose”）担任FP & A高级总监，该公司是一家上市的专业制药公司，专注于耳、鼻、喉和过敏专科医生治疗的疾病。从2016年7月到2018年2月，Pfanstiel先生担任Depuy Synthes Companies的支持全球战略营销高级总监，该公司是强生拥有的骨科和神经外科公司的特许经营权。在其职业生涯的早期，Pfanstiel先生曾在强生担任多个财务职位，包括杨森研发、LifeScan和Ethicon Endo-Surgery。Pfanstiel先生在Wabash学院获得物理学学士学位，在Clemson大学获得环境系统工程硕士学位，在印第安纳大学Kelley商学院获得MBA学位。
- Steven Pfanstiel,most recently worked at Marinus Pharmaceuticals, a publicly traded pharmaceutical company specializing in rare diseases and neuroscience, from April 2021 through March 2025, where he most recently served as Chief Financial Officer and Chief Operating Officer. From April 2021 to March 2023, he served as Chief Financial Officer at Marinus Pharmaceuticals. From January 2020 to March 2021, Mr. Pfanstiel previously served as Vice President, Finance of LifeScan, Inc. ("LifeScan"), a medical device company focused on the diabetes market, where he was responsible for supporting LifeScan's global commercial and development organizations, as well as its financial planning and analysis treasury functions. Before LifeScan, Mr. Pfanstiel served as Senior Director of FP&A at OptiNose, Inc. ("OptiNose"), a publicly traded specialty pharmaceutical company focused on diseases treated by ear, nose, and throat and allergy specialists, from February 2018 to January 2020. From July 2016 to February 2018, Mr. Pfanstiel served as Senior Director supporting Global Strategic Marketing for the DePuy Synthes Companies, a franchise of orthopedic and neurosurgery companies owned by Johnson & Johnson. Earlier in his career, Mr. Pfanstiel held various finance positions within Johnson & Johnson, including Janssen R&D, LifeScan, and Ethicon Endo-Surgery. Mr. Pfanstiel received his B.A. in Physics from Wabash College, his M.S. in Environmental Systems Engineering from Clemson University and his MBA from Indiana University, Kelley School of Business.
- Keith J. Sullivan
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- W. Andrew Macan
W. Andrew Macan负责监督所有法律、合规和公司治理事务，同时还在多个运营领域承担领导责任，包括商业运营、收入周期管理、报销战略、人力资源和质量保证。在加入公司之前，Macan先生于2018年10月至2020年1月担任Russell 2000多元化矿产公司U.S. Silica Holdings, Inc.的高级副总裁、总法律顾问和公司秘书。他曾于2013年10月至2018年10月在Axalta涂层系统，LLC担任越来越多的职责，最近担任美洲地区总法律顾问和首席合规官，以及从2003年10月至2013年10月担任丘博保险公司，其中担任副总裁、公司法律顾问和秘书超过8年。Macan先生的职业生涯始于Ballard Spahr LLP和Dechert LLP的私人执业。他获得了富兰克林与马歇尔学院的政府学士学位和埃默里大学法学院的法学博士学位，并获得了荣誉和荣誉勋章。
W. Andrew Macan has overseen all legal, compliance, and corporate governance matters while also taking on leadership responsibility across several operational areas, including commercial operations, revenue cycle management, reimbursement strategy, human resources, and quality assurance. Prior to joining the Company, Mr. Macan was Senior Vice President, General Counsel, and Corporate Secretary of U.S. Silica Holdings, Inc., a Russell 2000 diversified minerals company, from October 2018 until January 2020. He served in roles of increasing responsibility with Axalta Coating Systems, LLC, from October 2013 until October 2018, most recently as General Counsel and Chief Compliance Officer, Americas, and The Chubb Corporation, from October 2003 until October 2013, including as Vice President, Corporate Counsel, and Secretary for over 8 years. Mr. Macan began his career in private practice at Ballard Spahr LLP and Dechert LLP. He earned a B.A. in Government from Franklin & Marshall College and his J.D. from Emory University School of Law with distinction and Order of the Coif.- W. Andrew Macan负责监督所有法律、合规和公司治理事务，同时还在多个运营领域承担领导责任，包括商业运营、收入周期管理、报销战略、人力资源和质量保证。在加入公司之前，Macan先生于2018年10月至2020年1月担任Russell 2000多元化矿产公司U.S. Silica Holdings, Inc.的高级副总裁、总法律顾问和公司秘书。他曾于2013年10月至2018年10月在Axalta涂层系统，LLC担任越来越多的职责，最近担任美洲地区总法律顾问和首席合规官，以及从2003年10月至2013年10月担任丘博保险公司，其中担任副总裁、公司法律顾问和秘书超过8年。Macan先生的职业生涯始于Ballard Spahr LLP和Dechert LLP的私人执业。他获得了富兰克林与马歇尔学院的政府学士学位和埃默里大学法学院的法学博士学位，并获得了荣誉和荣誉勋章。
- W. Andrew Macan has overseen all legal, compliance, and corporate governance matters while also taking on leadership responsibility across several operational areas, including commercial operations, revenue cycle management, reimbursement strategy, human resources, and quality assurance. Prior to joining the Company, Mr. Macan was Senior Vice President, General Counsel, and Corporate Secretary of U.S. Silica Holdings, Inc., a Russell 2000 diversified minerals company, from October 2018 until January 2020. He served in roles of increasing responsibility with Axalta Coating Systems, LLC, from October 2013 until October 2018, most recently as General Counsel and Chief Compliance Officer, Americas, and The Chubb Corporation, from October 2003 until October 2013, including as Vice President, Corporate Counsel, and Secretary for over 8 years. Mr. Macan began his career in private practice at Ballard Spahr LLP and Dechert LLP. He earned a B.A. in Government from Franklin & Marshall College and his J.D. from Emory University School of Law with distinction and Order of the Coif.